Sophia Genetics, a Saint Sulpice, Switzerland-based developer of Data Driven Medicine (DDM), closed a new $15m Series C financing round.
The round was led by Omega founder and healthcare veteran Marc Coucke.
The company will use the funds to continue market expansion and broaden its range of genomic tests.
Led by Jurgi Camblong, CEO and co-founder, Sophia Genetics provides an analytics platform, Sophia DDM™, which holds machine learning based algorithms and hosts a large clinical genomics community.
The company, which previously received backing from Mike Lynch, founder of Invoke Capital, now supports more than 100 healthcare institutions across 20 countries including Oxford University Hospital, Hospices Civils de Lyon, Vall d’Hebron Hospital and Cologne University Hospital. They leverage analytics technology and advanced machine learning algorithms to analyze the genetic make-up of some common cancers and inherited conditions to more accurately and quickly diagnose thousands of patients.
Sophia has a team of 60 employees – two thirds of whom hold PhDs and are experts in genomics, bioinformatics, computational and data protection.